| 000 | 01467 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250516081446.0 | ||
| 264 | 0 | _c20120516 | |
| 008 | 201205s 0 0 eng d | ||
| 022 | _a1532-1827 | ||
| 024 | 7 |
_a10.1038/bjc.2012.60 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAtherly, A J | |
| 245 | 0 | 0 |
_aThe cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cMar 2012 |
||
| 300 |
_a1100-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnaplastic Lymphoma Kinase |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aCrizotinib |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xeconomics |
| 650 | 0 | 4 |
_aPrecision Medicine _xeconomics |
| 650 | 0 | 4 |
_aPyrazoles _xpharmacology |
| 650 | 0 | 4 |
_aPyridines _xpharmacology |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 |
_aReceptor Protein-Tyrosine Kinases _xantagonists & inhibitors |
| 700 | 1 | _aCamidge, D R | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 106 _gno. 6 _gp. 1100-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/bjc.2012.60 _zAvailable from publisher's website |
| 999 |
_c21582972 _d21582972 |
||